Literature DB >> 30116085

Silodosin for benign prostatic hypertrophy.

.   

Abstract

Entities:  

Year:  2018        PMID： 30116085      PMCID： PMC6091779          DOI： 10.18773/austprescr.2018.030

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  2 in total

1.  Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

Authors:  Christopher R Chapple; Francesco Montorsi; Teuvo L J Tammela; Manfred Wirth; Evert Koldewijn; Eldiberto Fernández Fernández
Journal:  Eur Urol       Date:  2010-11-10       Impact factor: 20.096

2.  Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.

Authors:  Leonard S Marks; Marc C Gittelman; Lawrence A Hill; Weining Volinn; Gary Hoel
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450
  2 in total
  1 in total

1.  Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment.

Authors:  Yogendra Keche; Nitin Gaikwad; Suryaprakash Dhaneria; Apoorva Joshi
Journal:  J Res Pharm Pract       Date:  2021-01-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.